India’s highest court ruled this week that Swiss pharmaceutical giant Novartis AG cannot patent its cancer drug Glivec, allowing drug-makers in India the freedom to continue producing generic versions.
India’s highest court ruled this week that Swiss pharmaceutical giant Novartis AG cannot patent its cancer drug Glivec, allowing drug-makers in India the freedom to continue producing generic versions.